Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00198510 · ClinicalTrials.gov registry record · Phase 3
Safety and Efficacy Study of Vitrase for Clearance of Severe Vitreous Hemorrhage
A Phase 3 study of Diabetic Retinopathy and Vitreous Hemorrhage, sponsored by Bausch & Lomb Incorporated.
- Completed
- Registry status
- Phase 3
- Development phase
- 750
- Enrollment target
- 20
- Study locations
NCT00198510 is a Phase 3 study of Diabetic Retinopathy and Vitreous Hemorrhage that has completed, run by Bausch & Lomb Incorporated. The registered enrollment target is 750 participants, below the 1,663-participant average among 57 other Diabetic Retinopathy trials with a reported enrollment target (55% lower). The trial reports 20 study locations across 5 states.
The verdict
NCT00198510, a Phase 3 study of Diabetic Retinopathy and Vitreous Hemorrhage, has completed, sponsored by Bausch & Lomb Incorporated.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 750 participants
- Enrollment target
- 20
- Study locations
Study Summary
The purpose of this study is to determine if intravitreal injection of Vitrase (ovine hyaluronidase) clears vitreous hemorrhage
Conditions Studied
Interventions
- DRUG Vitrase
Study Locations (20)
California
- Retina Vitreous Associates Medical Group - Beverly Hills
- Maria E. Castillejos, MD - Chula Vista
- Natural Vision - Fresno
- Eye Medical Center of Fresno - Fresno
- Jerry Sebag, MD - Huntington Beach
- University of California, Irvine - Irvine
- California VitreRetinal Center - Menlo Park
- Southern California Desert Retina Consultants - Palm Springs
- Retinal Consultants - Sacramento
- H. Richard McDonald, MD - San Francisco
- Santa Clara Valley Medical Centre - San Jose
- Robert L. Avery, MD - Santa Barbara
- Olive View/UCLA Medical Center - Sylmar
Colorado
- Retina Consultants of Southern Colorado - Colorado Springs
- University of Colorado Health Sciences Center - Denver
Connecticut
- Danbury Eye Physicians & Surgeons - Danbury
- New England Retina Associates - Hamden
Florida
- Florida Eye Clinic - Altamonte Springs
- Eye Centers of Florida - Fort Myers
Arizona
- Retina Centers, PC - Tucson
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 750 participants |
| Start Date | 1998-11 |
| Est. Completion | 2003-03 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00198510
The ClinicalTrials.gov registry entry for NCT00198510 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 750 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 1,663-participant average among 57 other Diabetic Retinopathy trials with a reported enrollment target (55% lower). The listed sponsor is Bausch & Lomb Incorporated, which has 174 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Diabetic Retinopathy appearing as the primary indexed condition, and to 1 intervention - of which Vitrase is the first listed.
NCT00198510 reports 20 study locations spanning 5 distinct geographic areas - top geographies include California, Colorado, Connecticut.
Frequently Asked Questions
What is clinical trial NCT00198510 about?
NCT00198510 is a clinical study titled "Safety and Efficacy Study of Vitrase for Clearance of Severe Vitreous Hemorrhage". The purpose of this study is to determine if intravitreal injection of Vitrase (ovine hyaluronidase) clears vitreous hemorrhage
What is the current status of trial NCT00198510?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 750 participants. The study started on 1998-11. Estimated completion is 2003-03.
What conditions does trial NCT00198510 study?
This clinical trial studies the following conditions: Diabetic Retinopathy, Vitreous Hemorrhage.
What interventions are being tested in trial NCT00198510?
The interventions under investigation include: Vitrase (DRUG).
Who is sponsoring clinical trial NCT00198510?
This trial is sponsored by Bausch & Lomb Incorporated, which has 174 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00198510 being conducted?
This trial has 20 study locations across Arizona, California, Colorado, Connecticut, Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Diabetic Retinopathy
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Fenofibrate for Prevention of DR Worsening
RECRUITING · Phase 3
-
A Multicenter, Randomized Study in Participants With Diabetic Retinopathy Without Center-involved Diabetic Macular Edema To Evaluate the Efficacy, Safety, and Pharmacokinetics of Ranibizumab Delivered Via the Port Delivery System Relative to the Comparator Arm
ACTIVE NOT RECRUITING · Phase 3
-
A Study to Evaluate the Efficacy and Safety of Tarcocimab Tedromer Compared With Sham Treatment in Participants With Diabetic Retinopathy (DR)
ACTIVE NOT RECRUITING · Phase 3
-
Octreotide Acetate in Microspheres in Patients With Diabetic Retinopathy
COMPLETED · Phase 3
-
Reduction in the Occurrence of Center-Involved Diabetic Macular Edema
COMPLETED · Phase 3
-
Anti-VEGF Treatment for Prevention of PDR/DME
COMPLETED · Phase 3
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.